Aclaris Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Aclaris Therapeutics (NASDAQ:ACRS) Third Quarter 2024 Results

Key Financial Results

• Revenue: US$4.35m (down 53% from 3Q 2023).
• Net loss: US$7.59m (loss narrowed by 74% from 3Q 2023).
• US$0.11 loss per share (improved from US$0.41 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aclaris Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 63%. Earnings per share (EPS) also missed analyst estimates by 88%.

Looking ahead, revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%.

Performance of the American Pharmaceuticals industry.

The company's shares are up 35% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Aclaris Therapeutics (1 is a bit unpleasant!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.